Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612184 | 0.85 | KDM4E (0.54) | KDM4EALDH1A1PYCR1HRH3 | |
| SCHEMBL14019814 | 0.84 | MEN1 (0.51) | HRH3MEN1KMT2A | |
| SCHEMBL14376647 | 0.83 | MCHR1 (0.46) | ALDH1A1HRH3MEN1KMT2A | |
| SCHEMBL17230510 | 0.83 | TSHR (0.49) | — | |
| SCHEMBL615299 | 0.82 | TSHR (0.56) | KDM4EMEN1KMT2A | |
| SCHEMBL69821 | 0.81 | PYCR1 (0.69) | KDM4EALDH1A1PYCR1HRH3HDAC8 | |
| SCHEMBL10187442 | 0.81 | PYCR1 (0.69) | KDM4EALDH1A1PYCR1HRH3MEN1 | |
| SCHEMBL3618020 | 0.81 | MEN1 (0.40) | KDM4EALDH1A1PYCR1MEN1KMT2A | |
| SCHEMBL20548501 | 0.79 | LPL (0.46) | HRH3MEN1KMT2AHDAC8HDAC6 | |
| SCHEMBL14376811 | 0.79 | CYP2A6 (0.46) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029754-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SW) | 2010-02-04 | — | — | US | disclosed |
| US-7572826-B2 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20060058522-A1 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058522-A1 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | NFKBIA, RELA, IKBKE | KDM4E 333/4885ALDH1A1 3513/4885PYCR1 1649/4885 |
| US-20100029754-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | NFKBIA, RELA, IKBKE | KDM4E 333/4885ALDH1A1 3513/4885PYCR1 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.